Press releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Apr 20, 2015Results Published in the Journal of American College of CardiologyToday the Journal of the American College of Cardiology published data confirming the long-term safety and efficacy of the Boston Scientific Corporation (NYSE: BSX) S-ICD System™ (subcutaneous...
Apr 16, 2015Boston Scientific Corporation (NYSE: BSX) is taking a new approach to evaluate the performance of the Vessix™ Renal Denervation System, initiating a study with a novel design to isolate the...
Apr 14, 2015Companies Plan to Accelerate Physician Training and Expand Utilization of Less-Invasive Endoscopy Technologies in ChinaBoston Scientific Corporation (NYSE: BSX), a leading global medical device company, announced the signing of a strategic alliance with Frankenman Medical Equipment Company, a recognized leader...
- Apr 1, 2015
Boston Scientific Corporation (NYSE: BSX) announces that it has signed a definitive agreement to acquire Xlumena, Inc., a venture-backed medical device company that develops, manufactures and...
Apr 1, 2015Boston Scientific Corporation (NYSE: BSX) will webcast a conference call on Tuesday, April 28, 2015 at 8 a.m. ET to review financial results and business highlights for the first quarter 2015. The...
Mar 24, 2015Novel Stroke Risk Reduction Option for Indicated Patients with Atrial FibrillationThis week, four patients in the United States received the first implants of the Boston Scientific Corporation (NYSE: BSX) WATCHMAN™ Left Atrial Appendage Closure (LAAC) Device. The WATCHMAN...
Mar 17, 2015Innovative device offers first-line treatment for patients at risk of sudden cardiac arrestBoston Scientific Corporation (NYSE: BSX) has received FDA and CE Mark approval of the EMBLEM™ Subcutaneous Implantable Defibrillator (S-ICD) System. The EMBLEM S-ICD System is a treatment...
Mar 13, 2015First-Of-Its-Kind Alternative to Long-Term Warfarin Therapy for Stroke Risk Reduction in Patients with Non-Valvular Atrial FibrillationBoston Scientific Corporation (NYSE: BSX) has received U.S. Food and Drug Administration (FDA) approval for the WATCHMAN Left Atrial Appendage Closure Device. The WATCHMAN Device offers a new...
Mar 3, 2015Boston Scientific Corporation (NYSE: BSX) announces the election of Charles J. Dockendorff and Stephen P. MacMillan to its board of directors, effective April 1, 2015. Two current members of the...
Mar 2, 2015Combined Business to Advance Patient Care with Leading Solutions Across Major Urology CategoriesBoston Scientific Corporation (NYSE: BSX) today announced that it has entered into a definitive agreement with Endo International plc (NASDAQ: ENDP) (TSX: ENL) to acquire the American Medical...
Feb 27, 2015Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Barclays 2015 Annual Healthcare Conference on March 10 in Miami Beach. Dan Brennan, executive vice president and chief...
Feb 26, 2015Boston Scientific Corporation (NYSE: BSX) announces 510(k) clearance and the first cases of the SpyGlass DS Direct Visualization System used for cholangioscopy and pancreatoscopy procedures. Built...
- Feb 25, 2015
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Cowen 35th Annual Healthcare Conference on March 4 in Boston. Dan Brennan, executive vice president and chief financial...
- Feb 17, 2015
Boston Scientific Corporation (NYSE: BSX) today announced the settlement of the breach of merger agreement lawsuit brought by Johnson & Johnson against Guidant Corporation, stemming from Boston...
- Feb 13, 2015
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the RBC Capital Markets 2015 Global Healthcare Conference on February 25 in New York City. Dan Brennan, executive vice...
- Feb 9, 2015
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Leerink 2015 Global Healthcare Conference on February 11 in New York City. Susan Lisa, vice president, Investor...
Feb 9, 2015Agreement Extends Reach of Lutonix DCB and Provides Physicians with a Comprehensive Solution to Prepare and Treat Diseased Femoropopliteal VesselsBoston Scientific Corporation (NYSE: BSX) and C. R. Bard, Inc. (NYSE: BCR) ("Bard") today announced that Boston Scientific will distribute the Lutonix® 035 Drug Coated Balloon Percutaneous...
- Feb 4, 2015
Boston Scientific Corporation (NYSE: BSX) generated sales of $1.887 billion during the fourth quarter ended December 31, 2014, compared to the company's guidance range for the quarter of $1.875 to...
Feb 3, 2015IndustryWeek recognition highlights manufacturing excellenceThe Boston Scientific (NYSE: BSX) Maple Grove Operations facility, Maple Grove, Minn., has been named a 2014 Best Plants winner by IndustryWeek magazine. IndustryWeek annually recognizes...
Feb 2, 2015Boston Scientific Corporation (NYSE: BSX) announces the launch and first U.S. implant of its line of Extended Longevity (EL) implantable cardioverter defibrillators (ICD), including DYNAGEN™ EL...
Jan 20, 2015Marlborough, Mass. (January 20, 2015) – Boston Scientific Corporation (NYSE: BSX), a global medical device company headquartered in Marlborough, Massachusetts, will co-sponsor the 2015...
Jan 15, 2015Boston Scientific Corporation (NYSE: BSX) will host and webcast an Investor Day business review meeting for the investment community on Friday, May 1, 2015. The meeting and webcast are scheduled...
- Jan 7, 2015
Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the fourth quarter and full year ended December 31, 2014 on...
-
Dec 22, 2014
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 33rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2015 in San Francisco. Mike Mahoney, president...
-
Dec 18, 2014
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Goldman Sachs CEOs Unscripted Healthcare Conference on Tuesday, January 6, 2015 in Boston. Mike Mahoney, president and...
-
Dec 12, 2014Significant Relief Achieved Using Advanced Illumina™ 3D Programming Software
New retrospective data evaluating the Boston Scientific Corporation (NYSE: BSX) Precision Spectra™ Spinal Cord Stimulator (SCS) System demonstrate that the device provided sustained, highly...
-
Nov 19, 2014
Boston Scientific has scored the highest rating of 100 percent in the Human Rights Campaign (HRC) Foundation's 2015 Corporate Equality Index (CEI). The top mark distinguishes the company as one of...
-
Nov 19, 2014EVOLVE II Trial Represents the First Successful U.S. Pivotal Trial of a Bioabsorbable Polymer Stent
In the first successful U.S. pivotal trial of a bioabsorbable polymer stent, the Boston Scientific (NYSE: BSX) SYNERGY™ Everolimus-Eluting Bioabsorbable Polymer Platinum Chromium Coronary Stent...
-
Nov 17, 2014
Boston Scientific Corporation (NYSE: BSX) announces the completion of the first U.S. procedures performed with the Symphion System, designed for the hysteroscopic removal of interuterine fibroids...
-
Nov 13, 2014New CPT Category I Code Facilitates Processing for U.S. Hospitals and Physicians
Boston Scientific Corporation (NYSE: BSX) announced that its subcutaneous implantable defibrillator (S-ICD System™) will have designated Current Procedural Terminology (CPT®) Category I codes...
-
Nov 5, 2014
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 2014 Stifel Healthcare Conference on Tuesday, November 18, 2014 in New York City. Dan Brennan, executive vice president...
-
Nov 4, 2014Event will be held in Chicago, Site of the 2014 American Heart Association Scientific Sessions
Boston Scientific Corporation (NYSE: BSX) today announced that it will be holding an analyst event on November 19, 2014 to provide an update on company interventional cardiology initiatives and...
-
Nov 3, 2014Data Will Focus on Long-Term Back Pain Relief Using the Boston Scientific Precision Spectra™ Spinal Cord Stimulator (SCS) System and Highlight Research on Stimulation Waveforms
Boston Scientific Corporation (NYSE: BSX) is reinforcing the company's commitment to developing innovative and effective therapies in neuromodulation. The company will present data on key clinical...
-
Oct 30, 2014
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 2014 Credit Suisse Annual Healthcare Conference on Tuesday, November 11, 2014 in Phoenix, AZ. Dan Brennan, executive...
-
Oct 22, 2014
Boston Scientific Corporation (NYSE: BSX) generated sales of $1.846 billion during the third quarter ended September 30, 2014, compared to the company's guidance range for the quarter of $1.790 to...
-
Oct 21, 2014World's First 32-contact SCS Surgical Leads Designed to Provide More Focused Pain Relief for Patients with Chronic Pain
Boston Scientific Corporation (NYSE: BSX) has received U.S. Food and Drug Administration (FDA) and CE Mark approval for the CoverEdge™ 32 and CoverEdge™ X 32 Surgical Leads, the world's first...
-
Oct 20, 2014First Patient Enrolled in PLATINUM Diversity Trial Evaluating Performance in Women, Black Americans, Latinos/Hispanics, Native Americans and Alaska Natives with Coronary Artery Disease
As part of its commitment to innovation and improving patient outcomes, Boston Scientific Corporation (NYSE: BSX) has initiated the PLATINUM Diversity trial to evaluate the clinical performance of...
-
Oct 16, 2014The innovative devices allow pacemaker patients access to full body MRI scans in 1.5 Tesla and 3.0 Tesla systems
Boston Scientific Corporation (NYSE: BSX) has received CE Mark approval for the ACCOLADETM pacemaker family. When implanted with the company's INGEVITYTM leads, ACCOLADE pacemakers are the first...
-
Oct 8, 2014Comprehensive Clinical Data from Randomized Trials Reviewed
After reviewing updated data and analysis for the Boston Scientific Corporation (NYSE: BSX) WATCHMAN™ Left Atrial Appendage Closure (LAAC) Device, the U.S. Food and Drug Administration (FDA)...
-
Oct 1, 2014
Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the third quarter ended September 30, 2014 on Wednesday, October...
-
Sep 23, 2014Data From REPRISE III Clinical Trial Designed to Support U.S. Regulatory Approval
Boston Scientific Corporation (NYSE: BSX) has initiated the REPRISE III clinical trial, a pivotal study to evaluate the safety and effectiveness of the Lotus™ Valve System in patients with...
-
Sep 17, 2014Vercise DBS System is the First DBS System Offering Precise Neural Targeting and a 25-Year Battery Life
Boston Scientific Corporation (NYSE: BSX) has received CE Mark for the Vercise™ Deep Brain Stimulation (DBS) System for the treatment of tremor, including the most common form of this movement...
-
Sep 15, 2014No Cases of Moderate or Severe Paravalvular Aortic Regurgitation at One Year
New data from the Boston Scientific (NYSE: BSX) clinical trial program of the Lotus™ Valve System continue to demonstrate strong performance as a less invasive treatment for patients with severe...
-
Sep 10, 2014Data Will Focus on Areas of Significant Unmet Patient Need, Including Coronary Artery Disease and Aortic Valve Disease
Beginning Saturday, Boston Scientific Corporation (NYSE: BSX) will present data that reinforce the company's commitment to advancing science for life and to developing innovative therapies in...
-
Sep 3, 2014
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 2014 Bank of America Merrill Lynch Global Healthcare Conference on September 17, 2014 in London, England. Michael...
-
Sep 2, 2014
Boston Scientific Corporation (NYSE: BSX) closed on its previously announced agreement to purchase the Interventional business of Bayer AG. The acquisition enhances the ability of Boston...
-
Aug 30, 2014Phase II feasibility trial provides first randomized sham-controlled data using vagus nerve stimulation to treat heart failure
Boston Scientific has released the primary endpoint results from its NEural Cardiac TherApy foR Heart Failure (NECTAR-HF) clinical trial, the first and only randomized sham-controlled clinical...
-
Aug 25, 2014
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 2014 Morgan Stanley Global Healthcare Conference on September 8 in New York, NY. Mike Mahoney, chief executive officer, and
-
Aug 19, 2014Companies Reach Agreement to Develop a New and Differentiated FFR Guidewire and Next Generation Boston Scientific Rotablator™ RotaWire™
Boston Scientific Corporation (NYSE: BSX) and ASAHI INTECC (Securities Code 7747, Second Section, Tokyo and Nagoya Stock Exchange) have formalized plans to develop a new, differentiated fractional...
-
Jul 24, 2014
Boston Scientific Corporation (NYSE: BSX) generated sales of $1.873 billion during the second quarter ended June 30, 2014, compared to the company's guidance range for the quarter of $1.840 to...